PNU-120596,a positive allosteric modulator of α7 nicotinic acetylcholine receptors,reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats
Restricted accessResearch articleFirst published online September, 2012
PNU-120596,a positive allosteric modulator of α7 nicotinic acetylcholine receptors,reverses a sub-chronic phencyclidine-induced cognitive deficit in the attentional set-shifting task in female rats
The α7 nicotinic acetylcholine receptors (nAChRs) have been highlighted as a target for cognitive enhancement in schizophrenia. Adult female hooded Lister rats received sub-chronic phencyclidine (PCP) (2 mg/kg) or vehicle i.p. twice daily for 7 days, followed by 7 days’ washout. PCP-treated rats then received PNU-120596 (10 mg/kg; s.c.) or saline and were tested in the attentional set-shifting task. Sub-chronic PCP produced a significant cognitive deficit in the extra-dimensional shift (EDS) phase of the task (p < 0.001, compared with vehicle). PNU-120596 significantly improved performance of PCP-treated rats in the EDS phase of the attentional set-shifting task (p < 0.001). In conclusion, these data demonstrate that PNU-120596 improves cognitive dysfunction in our animal model of cognitive dysfunction in schizophrenia, most likely via modulation of α7 nACh receptors.
BirrellJMBrownVJ (2000) Medial frontal cortex mediates perceptual attentional set-shifting in the rat. J Neurosci20: 4320–4324.
4.
BreeseCRLeeMJAdamsCESullivanBLogelJGillenKM. (2000) Abnormal regulation of high affinity nicotinic receptors in subjects with schizophrenia. Neuropsychopharmacology23: 351–364.
5.
BrownDCIINicholsJAThomasFDinhLAtzoriM (2010) Nicotinic modulation of auditory attentional shift in the rat. Behav Brain Res210: 273–279.
6.
ChanWKWongPT-HSheuF-S (2007) Frontal cortical α7 and α4β2 nicotinic acetylcholine receptors in working and reference memory. Neuropharmacology52: 1641–1649.
7.
EgertonARiedLMcGregorSCochranSMMorrisBJPrattJA (2008) Subchronic and chronic PCP treatment produces temporally distinct deficits in attentional set-shifting and prepulse inhibition in rats. Psychopharmacology (Berl)198: 37–49.
8.
FreedmanRHallMAdlerLELeonardS (1995) Evidence in post-mortem brain tissue for decreased numbers of hippocampal nicotinic receptors in schizophrenia. Biol Psychiatry38: 22–33.
9.
GoetghebeurPDiasR (2009) Comparison of haloperidol, risperidone, sertindole, and modafinil to reverse an attentional set-shifting impairment following subchronic PCP administration in the rats – a back translational study. Psychopharmacology (Berl)202: 287–293.
10.
Goldman-RakicPSCastnerSASvenssonTHSieverLJWilliamsGV (2004) Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction. Psychopharmacology (Berl)174: 3–16.
11.
GrayJARothBL (2007) Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr Bull33: 1100–1119.
12.
HarrisJGKongsSAllensworthDMartinLTregellasJSullivanB. (2004) Effects of nicotine on cognitive deficits in schizophrenia. Neuropsychopharmacology29: 1378–1385.
13.
HautMWCahillJCutlipWDStevensonJMMakelaEHBloomfieldSM (1996) On the nature of Wisconsin Card Sorting Test performance in schizophrenia. Psychiatry Res65: 15–22.
14.
HurstRSHajósMRaggenbassMWallTMHigdonNRLawsonJA (2005) A novel positive allosteric modulator of the α7 neuronal nicotinic acetylcholine receptor: in vitro and in vivo characterisation. J Neurosci25: 4396–4405.
15.
JonesCAWatsonDJGFoneKCF (2011) Animal models of schizophrenia. Br J Pharmacol164: 1162–1194.
16.
KeefeRSSweeneyJAGuHHamarRMPerkinsDOMcEnvoyJP. (2007) Effects of olanzapine, quetiapine, and risperidone on neurocognition function in early psychosis: a randomised, double-blind 52-week comparison. Am J Psychiatry164: 1061–1071.
17.
KolbBWilshawIQ (1983) Performance of schizophrenic patients on tests sensitive to left or right frontal temporal, or parietal function in neurological patients. J Nerv Ment Dis171: 435–443.
18.
KrauseRMBuissonBBertrandSCorringerPJGalziJLChangeuxJP. (1998) Ivermectin: a positive allosteric effector of the alpha 7 neuronal nicotinic acetylcholine receptor. Mol Pharmacol53: 283–294.
19.
LeiserSCBowlbyMRComeryTADunlopJ (2009) A cog in cognition: How the α7 nicotinic acetylcholine receptor is geared towards improving cognitive deficits. Pharmacol Ther122: 302–311.
LivingstonePDSrinivasanJKewJNCDawsonLAGottiCMorettiM. (2009) α7 and non-α7 nicotinic acetylcholine receptors modulate dopamine release in vitro and in vivo in the rat prefrontal cortex. Eur J Neurosci29: 539–550.
22.
MaelickeA (2000) Allosteric modulation of nicotinic receptors as a treatment strategy for Alzheimer’s disease. Dement Geriatr Cogn Disord11(Suppl 1): 11–18.
23.
McLeanSLBeckJPWoolleyMLNeillJC (2008) A preliminary investigation into the effects of antipsychotics on sub-chronic phencyclidine-induced deficits in attentional set-shifting in female rats. Behav Brain Res189: 152–158.
24.
McLeanSLGraysonBIdrisNFLesageASPembertonDJMackieC. (2011) Activation of α7 nicotinic receptors improves phencyclidine-induced deficits in cognitive tasks in rats: implications for therapy for cognitive dysfunction in schizophrenia. Eur Neuropsychopharmacol21: 333–343.
25.
NeillJCBarnesSCookSGraysonBIdrisNFMcLeanSL. (2010) Animal models of cognitive dysfunction and negative symptoms of schizophrenia: focus on NMDA receptor antagonism. Pharmacol Ther128: 419–432.
26.
PantelisCBarberFZBarnesTRENelsonHEOwenAMRobbinsTW (1999) Comparison of set shifting ability in patients with chronic schizophrenia and frontal lobe damage. Schizophr Res37: 251–270.
27.
QuickMWLesterRAJ (2002) Desensitisation of neuronal nicotinic receptors. J Neurobiol53: 457–478.
28.
RodeferJSMurphyERBaxterMG (2005) PDE10A inhibition reverses subchronic PCP-induced deficits in attentional set-shifting in rats. Eur J Neurosci21: 1070–1076.
29.
RodeferJSNguyenTNKarlssonArntJ (2008) Reversal of subchronic PCP-induced deficits in attentional set shifting in rats by Sertindole and a 5-HT6 receptor antagonist: Comparison among antipsychotics. Neuropsychopharmacology33: 2657–2666.
30.
RushforthSLAllisonCWonnacottSShoaibM (2010) Subtype-selective nicotinic agonists enhance olfactory working memory in normal rats: a novel use of the odour span task. Neurosci Lett471: 114–118.
31.
SaleemMMHarteMKMarshallKMNeillJC (2010) Investigation into cognitive function in first episode psychosis patients. Schizophr Res117: 215.
32.
SchreiberRDalmusMDe VryJ (2002) Effects of alpha 4/beta 2- and alpha 7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berl)159: 248–257.
33.
SmithRCSinghAInfanteMKhandatAKloosA (2002) Effects of cigarette smoking and nicotine nasal spray on psychiatric symptoms and cognition in schizophrenia. Neuropsychopharmacology27: 479–497.
34.
SnigdhaSLiZDaiJShahidMNeillJCMeltzerH (2008) Effect of PCP to attenuate DA efflux in rats performing the object recognition task: an in vivo investigation. Program No. 791.4/ TT40. 2008 Neuroscience Meeting Planner. Society for Neuroscience, Washington, 2008 (Online).
35.
WallaceTLCallahanPMTehimABertrandDTombaughGWangS. (2011) RG3487, a novel nicotinic α7 receptor partial agonist, improves cognition and sensorimotor gating in rodents. J Pharmacol Exp Ther336: 242–53.
36.
WhiteHKLevinED (2004) Chronic transdermal nicotine patch treatment effects on cognitive performance in age-associated memory impairment. Psychopharmacology (Berl) 171: 465–71.
37.
YoungGTZwartRWalkerASSherEMillarNS (2008) Potentiation of alpha7 nicotinic acetylcholine receptors via an allosteric transmembrane site. Proc Natl Acad Sci U S A105: 14686–14691.
38.
ZhaoXMarszalecWTothPTHuangJYehJZNarahashiT (2006) In vitro galantamine-memantine co-application: mechanism of beneficial action. Neuropharmacology51: 1181–1191.
